# Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)

> **NCT01927705** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kang Stem Biotech Co., Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** FURESTEM-AD Inj.

## Key facts

- **NCT ID:** NCT01927705
- **Lead sponsor:** Kang Stem Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01927705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01927705, "Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01927705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*